Form 8-K - Current report:
SEC Accession No. 0001815776-24-000064
Filing Date
2024-10-28
Accepted
2024-10-28 08:09:55
Documents
16
Period of Report
2024-10-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lenz-20241027.htm   iXBRL 8-K 27316
2 EX-99.1 exhibit991-jixingdataannou.htm EX-99.1 24050
6 corxellogo.jpg GRAPHIC 3131
7 lenzlogo.jpg GRAPHIC 2890
  Complete submission text file 0001815776-24-000064.txt   197282

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20241027.xsd EX-101.SCH 1770
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20241027_lab.xml EX-101.LAB 23433
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20241027_pre.xml EX-101.PRE 13570
19 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20241027_htm.xml XML 3041
Mailing Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075
Business Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 241398461
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)